Proposal for "Strengthening the Management of Rheumatism and Immune Diseases and Chronic Diseases in China": Establishing an independent rheumatism department in primary hospitals

In order to promote the development of rheumatism and immunology and optimize the management of patients with rheumatism, the 2021 Annual Academic Conference of the Chronic Disease Management Group of the Rheumatology Committee of the Cross-Strait Medical and Health Exchange Association and the 6th International Forum on Rheumatism Management On the previous page, well-known experts and scholars from the field of rheumatism and immunity, as well as medical workers in related disciplines, gathered to discuss in depth the management models and strategies of various rheumatic diseases and chronic diseases, exchanged and shared new trends in rheumatism and immunology at home and abroad.
Promote the innovation of the management model for chronic diseases of rheumatism and immune diseases, strengthen regional exchanges and cooperation, and promote the construction of a chronic disease management system
.
Professor Liu Yi, director of the Department of Rheumatology and Immunology of West China Hospital of Sichuan University, said that in recent years, many hospitals in various regions of China have improved their management of chronic diseases by carrying out management of rheumatic diseases, and have achieved certain results
.
"However, there is still a lot of room for improvement in diagnosis, treatment and management.
The disease management chain can also extend to both ends.
Through the establishment of standardized processes and homogeneous management practices, the professional capabilities of medical staff can be improved, and the patients with rheumatoid immune diseases can be deepened.
To understand the disease, improve the medical experience, enhance patient compliance, better improve the patient’s prognosis, and reduce the burden on the country and the family
.
” To this end, the Cross-Strait Medical and Health Exchange Association Rheumatism and Immunology Special Committee Chronic Disease Management The academic group issued the proposal of "Strengthening the Management of Rheumatism and Immunology and Chronic Disease in China", proposing proposals from the four dimensions of medical staff, patients and families, medical institutions, and administrative power, including the establishment of a rheumatism and chronic disease management team to strengthen rheumatism and immunity Specialist nurses play a leading role in patient management, actively establish a multidisciplinary team, encourage and promote the application of new information technology in the management of rheumatism and immune diseases; strengthen the popularization and education of patients and family members, and encourage patient groups to establish rheumatism The chronic disease management team actively develops mutual assistance; encourages cooperation between medical institutions of different levels and different regions; establishes independent rheumatism departments of general hospitals and grassroots hospitals above the second level, and trains full-time rheumatology practitioners; strengthens the popularization of the concept of chronic disease management and The construction of the system, increase medical insurance investment, and include rheumatoid arthritis, ankylosing spondylitis and other rheumatic diseases into the national chronic disease management system
.
"Rheumatic immune disease is a serious chronic disease with complex etiology and a long course of disease, which often leads to body dysfunction and is called'undead cancer'..
"Professor Li Ting, deputy chief physician of the Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, said that taking China's rheumatoid arthritis as an example, the disability rate of patients with a disease course of 5 to 10 years is 43.
48%, and the disease course is more than 10 years.
The total disability rate is as high as 30% to 40%, and the disability rate for more than 15 years is 61.
25%
.
Although rheumatism cannot be completely cured at present, as long as early diagnosis and standard treatment are achieved, most patients can be well controlled.
Progress and obtain a higher quality of life
.
"To achieve such a treatment goal, a chronic disease management system that meets the national conditions needs to be coordinated
.
When talking about chronic disease management, Professor Yang Jing, director of the Department of Rheumatology and Immunology of Mianyang Central Hospital, emphasized that the management of chronic disease of rheumatism and immunity refers to the organization of multidisciplinary personnel, such as specialist doctors, nurses, pharmacists, and rehabilitation.
Physicians, psychiatrists, nutritionists, etc.
form a medical team to provide comprehensive, continuous, and active management for patients with chronic diseases, so as to achieve a scientific management model that delays the disease process, reduces the disability rate, promotes health, and reduces medical costs
Chronic disease management has been proven internationally to have advantages in monitoring the complications of rheumatoid arthritis and guiding patients in self-assessment.
It is beneficial to the health outcomes of patients with rheumatoid arthritis and can reduce medical costs
.
" It is hoped that this initiative will further arouse the attention of all sectors of society to the entire management of rheumatism and immune diseases, promote the construction of China's chronic disease management system, improve the diagnosis and treatment of patients with rheumatism and immune diseases, and optimize the allocation of resources for diagnosis and treatment of rheumatism and immune diseases
.
As an enterprise representative who has accumulated rich experience in multiple treatment fields, Dr.
Junyang Cao, Chief Medical Officer of Pfizer Biopharmaceutical Group in China, said: "Pfizer has always been committed to becoming an important partner of China's healthcare system
.
Patients are always at the center of all our work.
Under the initiative of'Strengthening the Management of China's Rheumatism and Immunology and Chronic Disease Management', Pfizer will promote the establishment and improvement of China's rheumatism and immunology and chronic disease management system through extensive academic cooperation.
, To help achieve the goal of'Healthy China 2030'
.
"